Replies to post #28134 on Humanigen Inc (HGENQ)

[MWM]

Anyone who wants to spin it differently is doing just that, Spinning!

Humanigen will initiate a randomized, multicenter, potentially registrational, Phase 2 study to evaluate the efficacy and safety of lenzilumab combined with all commercially available CD19 CAR-T therapies in DLBCL. The study plans to enroll approximately 150 patients and the protocol is being submitted to FDA.